Literature DB >> 23484795

Regulatory innovation and drug development for early-stage Alzheimer's disease.

Nicholas Kozauer1, Russell Katz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23484795     DOI： 10.1056/NEJMp1302513

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  83 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

2.  Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Authors:  Gad A Marshall; Natacha Lorius; Joseph J Locascio; Bradley T Hyman; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 3.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

4.  Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a.

Authors:  Yoosoo Yang; Jaewook Kim; Hye Yun Kim; Nayeon Ryoo; Sejin Lee; YoungSoo Kim; Hyewhon Rhim; Yeon-Kyun Shin
Journal:  Cell Rep       Date:  2015-08-13       Impact factor: 9.423

5.  Choosing Alzheimer's disease prevention clinical trial populations.

Authors:  Joshua D Grill; Sarah E Monsell
Journal:  Neurobiol Aging       Date:  2013-10-09       Impact factor: 4.673

6.  The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease.

Authors:  Laura Brennan; Andrew Siderowf; Jonathan D Rubright; Jacqueline Rick; Nabila Dahodwala; John E Duda; Howard Hurtig; Matthew Stern; Sharon X Xie; Lior Rennert; Jason Karlawish; Judy A Shea; John Q Trojanowski; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2016-02-21       Impact factor: 4.891

Review 7.  Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors:  David Hsu; Gad A Marshall
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

8.  Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).

Authors:  A S Atkins; I Stroescu; N B Spagnola; V G Davis; T D Patterson; M Narasimhan; P D Harvey; R S E Keefe
Journal:  J Prev Alzheimers Dis       Date:  2015-06

Review 9.  A quantitative neural network approach to understanding aging phenotypes.

Authors:  Jessica A Ash; Peter R Rapp
Journal:  Ageing Res Rev       Date:  2014-02-15       Impact factor: 10.895

Review 10.  Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment.

Authors:  Ferenc Deak; Willard M Freeman; Zoltan Ungvari; Anna Csiszar; William E Sonntag
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-11-20       Impact factor: 6.053
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.